Ankerstar Wealth
ARQT icon

Ankerstar Wealth’s Arcutis Biotherapeutics ARQT Stock Holding History

Ankerstar Wealth’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$185 Buy
+7
New +$183 ﹤0.01% 949

Other funds holding ARQT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Ankerstar Wealth's ARQT Position: Q3 2026 in Review

Ankerstar Wealth opened a new position in Arcutis Biotherapeutics (ARQT) in Q3 2026: 7 shares worth $185. The stake represents ﹤0.01% of the portfolio and ranks #949 among its holdings.

212 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Ankerstar Wealth held 7 shares of Arcutis Biotherapeutics worth $185 as of Q3 2026.
  • Arcutis Biotherapeutics was a new Ankerstar Wealth position in Q3 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Ankerstar Wealth's portfolio in Q3 2026, its #949 holding.
  • 212 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Ankerstar Wealth's 13F filing for Q3 2026, filed 13 Nov 2026.